Lung Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People aged 18 or older
- People who have previously been diagnosed with breast cancer or lung cancer through a tissue sample
- People who have a confirmed diagnosis of cancer that has spread to the membranes surrounding the brain and spinal cord (called leptomeningeal metastases), shown by both a positive spinal fluid test and specific scan findings
- People who have MRI scan results showing cancer involvement along the cervical, thoracic, or lumbar spine
- People with a life expectancy of at least 6 weeks
- People whose general physical functioning falls within a certain range on a standard medical scale (ECOG score of 0–3, where 0 means fully active and 3 means limited self-care) (confirm with trial site)
- People who have recovered from any nerve-related side effects of previous treatments
- People whose blood platelet count and white blood cell levels meet minimum thresholds set by the trial (confirm with trial site for exact values)
- People whose liver and kidney function meet the levels required by the trial (confirm with trial site for exact values)
- People who are able to give written consent, either personally or through a legal representative
- People whose body shape and size are suitable for wearing the treatment device
- People who are willing to wear the device for an average of at least 18 hours per day
- People who are willing to attend scheduled check-up visits and complete required assessments
- People who do not have another illness or situation that would make it hard to fairly assess the safety of the treatment
- People who are able to start the study treatment within 14 days of registering for the trial
Who may not be able to join:
- People currently receiving certain high-dose chemotherapy drugs, specifically high-dose methotrexate, high-dose thiotepa, or high-dose cytarabine (other systemic cancer treatments are generally permitted)
- People who have had radiation therapy to the brain or spinal cord within the past 2 weeks
- People who have had chemotherapy delivered directly into the spinal fluid within the past week
- People who are pregnant or breastfeeding, or people of childbearing potential who are not willing to use effective contraception
- People with an uncontrolled or untreated infection, including active hepatitis or HIV
- People currently taking part in another clinical trial, or who have received an investigational treatment within the past 14 days (or longer, if that treatment is known to have delayed side effects)
- People with a known allergy to the hydrophilic gel used to attach the treatment device to the skin
- People who have surgical hardware (such as titanium rods, screws, or fixation devices) in the area of the spine where treatment would be applied
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Wendy J. Sherman, MD, Mayo Clinic
Phone: 855-776-0015
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Incidence of significant toxicity of tumor treating fields (TTFs); Feasibility of TTFs - completion of at least 28 days of TTF therapy
Can't join this trial?
Data last synced from ClinicalTrials.gov: 15 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.